Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV001092537 | SCV001249082 | pathogenic | not provided | 2019-04-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000985137 | SCV001586766 | pathogenic | Aicardi-Goutieres syndrome 5 | 2024-02-07 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Met216Valfs*2) in the SAMHD1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SAMHD1 are known to be pathogenic (PMID: 19525956, 22461318). This variant is present in population databases (rs768019897, gnomAD 0.007%). This premature translational stop signal has been observed in individual(s) with Aicardi-Goutieres syndrome (PMID: 26273690, 28454995). ClinVar contains an entry for this variant (Variation ID: 800933). For these reasons, this variant has been classified as Pathogenic. |
Baylor Genetics | RCV000985137 | SCV003834977 | pathogenic | Aicardi-Goutieres syndrome 5 | 2021-05-24 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV005029544 | SCV005661837 | likely pathogenic | Aicardi-Goutieres syndrome 5; Chilblain lupus 2 | 2024-05-09 | criteria provided, single submitter | clinical testing | |
Biochemical Molecular Genetic Laboratory, |
RCV000985137 | SCV001133126 | likely pathogenic | Aicardi-Goutieres syndrome 5 | 2019-09-26 | no assertion criteria provided | clinical testing |